Anti-NAC2/ SLC8A2/ NCX2 monoclonal antibody

Anti-NAC2/ SLC8A2/ NCX2 antibody for FACS & in-vivo assay

Target products collectionGo to SLC8A2/SLC8A2 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-MP1669-Ab-1/ GM-Tg-hg-MP1669-Ab-2Anti-Human SLC8A2 monoclonal antibodyHuman
GM-Tg-rg-MP1669-Ab-1/ GM-Tg-rg-MP1669-Ab-2Anti-Rat SLC8A2 monoclonal antibodyRat
GM-Tg-mg-MP1669-Ab-1/ GM-Tg-mg-MP1669-Ab-2Anti-Mouse SLC8A2 monoclonal antibodyMouse
GM-Tg-cynog-MP1669-Ab-1/ GM-Tg-cynog-MP1669-Ab-2Anti-Cynomolgus/ Rhesus macaque SLC8A2 monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-MP1669-Ab-1/ GM-Tg-felg-MP1669-Ab-2Anti-Feline SLC8A2 monoclonal antibodyFeline
GM-Tg-cang-MP1669-Ab-1/ GM-Tg-cang-MP1669-Ab-2Anti-Canine SLC8A2 monoclonal antibodyCanine
GM-Tg-bovg-MP1669-Ab-1/ GM-Tg-bovg-MP1669-Ab-2Anti-Bovine SLC8A2 monoclonal antibodyBovine
GM-Tg-equg-MP1669-Ab-1/ GM-Tg-equg-MP1669-Ab-2Anti-Equine SLC8A2 monoclonal antibodyEquine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-MP1669-Ab-1/ GM-Tg-hg-MP1669-Ab-2; GM-Tg-rg-MP1669-Ab-1/ GM-Tg-rg-MP1669-Ab-2;
GM-Tg-mg-MP1669-Ab-1/ GM-Tg-mg-MP1669-Ab-2; GM-Tg-cynog-MP1669-Ab-1/ GM-Tg-cynog-MP1669-Ab-2;
GM-Tg-felg-MP1669-Ab-1/ GM-Tg-felg-MP1669-Ab-2; GM-Tg-cang-MP1669-Ab-1/ GM-Tg-cang-MP1669-Ab-2;
GM-Tg-bovg-MP1669-Ab-1/ GM-Tg-bovg-MP1669-Ab-2; GM-Tg-equg-MP1669-Ab-1/ GM-Tg-equg-MP1669-Ab-2
Products NameAnti-SLC8A2 monoclonal antibody
Formatmab
Target NameSLC8A2
Protein Sub-locationTransmembrane Protein
Category of antibodyFACS/Biofunctional Antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)		IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD).
TagFc
Products descriptionPre-made anti-SLC8A2 benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenProducts DevelopingMulti-species NAC2/ SLC8A2/ NCX2 VLP (virus-like particle) (Products Developing)


    Target information

    Target IDGM-MP1669
    Target NameSLC8A2
    Gene ID6543,110891,140447,718243,484420,101097856,535881,100146819
    Gene Symbol and SynonymsNCX2,SLC8A2
    Uniprot AccessionQ9UPR5,P48768
    Uniprot Entry NameNAC2_HUMAN,NAC2_RAT
    Protein Sub-locationTransmembrane Protein
    Category
    DiseaseN/A
    Gene EnsemblENSG00000118160
    Target ClassificationN/A

    The target: SLC8A2, gene name: SLC8A2, also named as NCX2. Predicted to enable calcium:cation antiporter activity involved in regulation of postsynaptic cytosolic calcium ion concentration and calcium:sodium antiporter activity. Predicted to be involved in several processes, including inorganic cation transmembrane transport; learning or memory; and regulation of short-term neuronal synaptic plasticity. Predicted to act upstream of or within several processes, including modulation of chemical synaptic transmission; regulation of action potential firing pattern; and response to ischemia. Part of presynapse. Biomarker of Alzheimer's disease. [provided by Alliance of Genome Resources, Apr 2022].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.